Recombinant Mouse ACE2 Protein, N-His from ProteoGenix; catalogue ARO-P10488; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Mouse ACE2 Protein, also known as angiotensin-converting enzyme 2, is a type I transmembrane glycoprotein that plays a crucial role in the renin-angiotensin system (RAS). It is a key component of the cardiovascular and immune systems, and has been extensively studied for its role in various diseases, including cardiovascular diseases and viral infections.
Recombinant Mouse ACE2 Protein is a 805-amino acid protein with a molecular weight of approximately 90 kDa. It consists of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. The extracellular domain contains the active site of the enzyme, which is a zinc-dependent metalloprotease domain. This domain is responsible for the cleavage of angiotensin II, a vasoconstrictor, into angiotensin 1-7, a vasodilator.
The main function of Recombinant Mouse ACE2 Protein is to regulate the RAS by converting angiotensin II to angiotensin 1-7. This process helps to maintain blood pressure and fluid balance in the body. In addition, Recombinant Mouse ACE2 Protein also has a protective role in the cardiovascular system by inhibiting the production of reactive oxygen species and reducing inflammation.
Aside from its role in the RAS, Recombinant Mouse ACE2 Protein has also been found to have a crucial role in viral infections. It serves as the cellular receptor for the severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerged SARS-CoV-2, which causes COVID-19. The binding of the virus to Recombinant Mouse ACE2 Protein allows for viral entry and infection of host cells.
Recombinant Mouse ACE2 Protein has various applications in both research and therapeutic fields. In research, it is used as a tool to study the role of RAS in different diseases, such as hypertension and heart failure. It is also utilized in the study of viral infections, particularly in understanding the mechanism of viral entry and developing potential treatments.
In the therapeutic field, Recombinant Mouse ACE2 Protein has shown promising results in the treatment of cardiovascular diseases. Its ability to regulate the RAS and reduce inflammation makes it a potential target for the treatment of hypertension, heart failure, and other cardiovascular conditions. In addition, there are ongoing studies on the use of Recombinant Mouse ACE2 Protein as a potential treatment for COVID-19, as it has been shown to block viral entry and reduce lung injury in animal models.
In summary, Recombinant Mouse ACE2 Protein is a crucial protein with important roles in both the cardiovascular and immune systems. Its structure, activity, and application have been extensively studied, and it has shown potential as a therapeutic target for various diseases, including cardiovascular diseases and viral infections. Further research and development of Recombinant Mouse ACE2 Protein could lead to new treatments and improve our understanding of these complex diseases.
ProteoGenix catalogue number ARO-P10488. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 13.84 kDa; Fragment: Ser617-Gly716; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
